Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Kaan KavakliF DemartisM KarimiP EshghiD NemeH ChambostL SommerM ZakG BensonPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2017)
Data collected during the SMART-7™ study revealed no treatment-related safety issues and no FVII-binding antibodies for patients treated with NovoSeven® under real-world conditions.